StockGuide AI
Track Stocks
EN RU ES
Immunovant

Immunovant

Price: 31.18

Company and Business Model

Immunovant is a biotechnology company focused on developing innovative therapies for autoimmune diseases. Its core product is IMVT-1401, a monoclonal antibody designed to treat conditions such as myasthenia gravis. The company primarily operates in the healthcare sector, with its main revenue source being potential future sales of its therapeutic products. Immunovant is currently in the clinical development stage, with no commercialized products generating revenue.

Investment Profile

The investment profile of Immunovant is more aligned with growth investors due to its focus on developing new therapies and the potential for significant future revenue, albeit with high associated risks. The stock may not appeal to dividend or value investors given the lack of current profitability and established revenue streams.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
-2.78 Risk
EPS surprise
-21.7% worse than expected
20d volatility
8.4% normal
FMP / FinFeed data updated: 2026-06-06

Forecast impact

neutral
Target Raised · H.C. Wainwright · valid until 2026-06-20 · updated 2026-06-11
Target +28.3% target fill 78.0%
Reaction D5 -5.92% · D10 -9.72%
Impact Potential 0 · Risk 0 up to 30 days or until target is reached
Reco: Sell Potential: 41 Risk: 69 Updated: 2026-06-11 05:21
How recommendation works
Why AI thinks so:
Weak fundamentals and high risk limit upside potential.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-03 02:43 Hold Sell Weak fundamentals and negative momentum raise significant concerns.
2026-05-22 02:48 Sell Hold Strong recent performance, but fundamentals remain weak.
2026-05-16 02:50 Hold Sell Weak fundamentals and negative momentum raise significant risk.
Analyst forecasts
Date Analyst Action Target Price Then
2026-05-21 10:35 H.C. Wainwright Target Raised — → 40 35.56
2026-01-06 12:55 Wolfe Research Rating Upgraded — → 50 24.97
2025-12-18 13:29 Guggenheim Target Lowered 44 → 41 26.2689